Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04879329
Title A Study of Disitamab Vedotin Alone and With Pembrolizumab in Urothelial Cancer That Expresses HER2
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Seagen Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | CAN


No variant requirements are available.